WASHINGTON — Tracy Beth Høeg, the acting director of the FDA’s Center for Drug Evaluation and Research, is departing the agency, as confirmed by an email obtained by STAT. This announcement follows closely on the heels of Commissioner Marty Makary’s resignation, creating a significant leadership vacuum within the agency.
In a post on X, Høeg stated, “today I was fired… I learned so much & leave with no regrets.” This abrupt change raises concerns about the stability and direction of the FDA’s drug regulatory processes, particularly at a time when the agency is under scrutiny for its handling of drug approvals and public health initiatives. Michael Davis, the current deputy director, will step in as acting director, but the lack of a permanent leadership structure may hinder the FDA’s ability to effectively navigate ongoing challenges in the pharmaceutical landscape.
The implications of this leadership shift could reverberate across the industry, affecting regulatory timelines and the overall confidence of stakeholders in the FDA’s decision-making processes.
Use the database as your supply chain compass →
